Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ProQR Therapeutics (PRQR) Operating Income (2016 - 2025)

ProQR Therapeutics' Operating Income history spans 5 years, with the latest figure at -$10.6 million for Q4 2025.

  • On a quarterly basis, Operating Income rose 1.7% to -$10.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$49.0 million, a 48.58% decrease, with the full-year FY2025 number at -$50.6 million, down 55.31% from a year prior.
  • Operating Income hit -$10.6 million in Q4 2025 for ProQR Therapeutics, up from -$13.2 million in the prior quarter.
  • Over the last five years, Operating Income for PRQR hit a ceiling of -$3.9 million in Q2 2024 and a floor of -$20.0 million in Q3 2022.
  • Historically, Operating Income has averaged -$12.6 million across 5 years, with a median of -$12.0 million in 2022.
  • Biggest five-year swings in Operating Income: surged 59.75% in 2023 and later plummeted 257.65% in 2025.
  • Tracing PRQR's Operating Income over 5 years: stood at -$19.8 million in 2021, then soared by 35.87% to -$12.7 million in 2022, then surged by 46.95% to -$6.7 million in 2023, then plummeted by 59.73% to -$10.8 million in 2024, then grew by 1.7% to -$10.6 million in 2025.
  • Business Quant data shows Operating Income for PRQR at -$10.6 million in Q4 2025, -$13.2 million in Q3 2025, and -$13.9 million in Q2 2025.